Industry Briefs: October 29, 2012
A roundup of additional company and people news from pharmaceutical and biopharmaceutical companies, their suppliers, and contract-service providers.
Company News
AnGes has entered into a definitive agreement with Mitsubishi Tanabe Pharma for the exclusive marketing rights of Collategene (DNA plasmid with hepatocyte growth factor gene) for treating for peripheral arterial disease in the United States. Read More
DSM Pharmaceutical Products has announced a biologics development and manufacturing agreement with Paranta Biosciences, for Paranta’s lead recombinant human protein for DSM’s at their Brisbane, Australia, facility. Read More
People News
Coldstream Laboratories has appointed Eric W. Smart as president and CEO. Read More
Eli Lilly has named Melissa Barnes as chief ethics and compliance officer, and senior vice-president. Barnes will replace Anne Nobles, following her retirement at the end of 2012. Read More
Spectrum Pharmaceuticals has appointed Joseph Turgeon as senior vice-president of sales and commercial operations. Read More
Drug Solutions Podcast: Novel Drug Delivery Approaches: Refining AAV Vector Deliveries
May 30th 2025In this podcast episode, we discuss novel approaches to drug delivery, specifically regarding adeno-associated virus (AAV) vectors, as viewed by two industry experts who recently exhibited at the annual ASGCT meeting.
Transformations in Drug Development for Cell and Gene Therapies
March 28th 2025As a recognized leader in immunophenotyping for clinical trials, Kevin Lang from PPD discusses how spectral flow cytometry is transforming drug development, particularly in cell and gene therapies like CAR-T. He also dives into his award-winning research, including his 2024 WRIB Poster Award-winning work, and his insights from presenting at AAPS PharmSci360.
A Novel, Enhanced, and Sustainable Approach to Audit Trail Review
July 4th 2025Eli Lilly and Company developed an innovative and sustainable approach to audit trail review (ATR) aimed at reducing the ATR burden while adhering to regulatory expectations and data integrity (DI) principles. The process has transformed employees' understanding of ATR and complemented the DI by design approach, leading to better system designs that meet expected controls and reduce non-value-added data reviews.
